In an internal review of collective Target Selector results of patients with lung cancer, slightly over 20% had KRAS exon 2 mutations and more than 20% showed activating mutations, whereas only 1.69% of patients had BRAF mutations. This evidence concerns the gene BRAF and lung cancer.